Prelude Therapeutics Ownership 2024 | Who Owns Prelude Therapeutics Now?
Institutional Ownership
1.87%
Insider Ownership
9.06%
Retail Ownership
89.07%
Institutional Holders
16.00
Prelude Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14.40% | 0.83% | 10,909,256 | - | - | 41,564,265 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 13.37% | 0.49% | 10,123,824 | - | - | 38,571,769 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5.46% | 0.26% | 4,133,000 | - | - | 15,746,730 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 3.39% | 0.52% | 2,568,287 | - | - | 9,785,173 | Jun 30, 2024 |
| BLACKROCK INC. | 1.41% | 0.00% | 1,068,916 | -28,558 | -2.60% | 4,072,569 | Jun 30, 2024 |
| VANGUARD GROUP INC | 1.33% | 0.00% | 1,010,565 | -6,434 | -0.63% | 3,850,253 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 891,298 | -50,673 | -5.38% | 3,397,000 | Jun 30, 2024 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.69% | 0.00% | 522,375 | 14,226 | 2.80% | 1,990,249 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.48% | 0.00% | 361,951 | 319 | 0.09% | 1,379,205 | Jun 30, 2024 |
| SIO CAPITAL MANAGEMENT, LLC | 0.42% | 0.33% | 320,394 | - | - | 1,220,701 | Jun 30, 2024 |
| MORGAN STANLEY | 0.38% | 0.00% | 287,354 | -8,851 | -2.99% | 1,094,820 | Jun 30, 2024 |
| STATE STREET CORP | 0.28% | - | 211,746 | 305 | 0.14% | 806,752,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.27% | 0.00% | 206,600 | -38,200 | -15.60% | 787,146 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.21% | 0.00% | 160,652 | - | - | 612,084 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | 0.00% | 128,033 | 663 | 0.52% | 487,806 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.16% | 0.00% | 124,686 | 2,539 | 2.08% | 475,053,000 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.16% | 0.01% | 123,600 | - | - | 470,916 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.10% | - | 74,923 | 7,496 | 11.12% | 285,457 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.09% | 0.00% | 70,045 | -2,217 | -3.07% | 266,871 | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.06% | 0.00% | 48,727 | -15,160 | -23.73% | 185,650 | Jun 30, 2024 |
Prelude Therapeutics's largest institutional shareholder is ORBIMED ADVISORS LLC, holding 14.40% of the company's total share outstanding, currently valued at $41.56M. The top 10 institutional shareholders own together 42.13% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14.40% | 0.83% | 10,909,256 | - | - | 41,564,265 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 3.39% | 0.52% | 2,568,287 | - | - | 9,785,173 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 13.37% | 0.49% | 10,123,824 | - | - | 38,571,769 | Jun 30, 2024 |
| SIO CAPITAL MANAGEMENT, LLC | 0.42% | 0.33% | 320,394 | - | - | 1,220,701 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5.46% | 0.26% | 4,133,000 | - | - | 15,746,730 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.16% | 0.01% | 123,600 | - | - | 470,916 | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.06% | 0.00% | 48,727 | -15,160 | -23.73% | 185,650 | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | 0.02% | 0.00% | 18,839 | 18,839 | 100.00% | 71,777 | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.01% | 0.00% | 11,074 | -2,772 | -20.02% | 42,192 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.05% | 0.00% | 35,283 | 10,248 | 40.93% | 134,428 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.27% | 0.00% | 206,600 | -38,200 | -15.60% | 787,146 | Jun 30, 2024 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.69% | 0.00% | 522,375 | 14,226 | 2.80% | 1,990,249 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.21% | 0.00% | 160,652 | - | - | 612,084 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.01% | 0.00% | 7,064 | 3,717 | 111.05% | 26,914 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 891,298 | -50,673 | -5.38% | 3,397,000 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.06% | 0.00% | 43,135 | -17,462 | -28.82% | 164,344 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.02% | 0.00% | 17,761 | 17,761 | 100.00% | 67,669 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.03% | 0.00% | 22,110 | - | - | 83,000 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.09% | 0.00% | 70,045 | -2,217 | -3.07% | 266,871 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.02% | 0.00% | 12,345 | -7,721 | -38.48% | 47,034 | Jun 30, 2024 |
The largest Prelude Therapeutics shareholder by % of total assets is ORBIMED ADVISORS LLC. The company owns 10.91M shares of Prelude Therapeutics (PRLD), representing 0.83% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| Y-INTERCEPT (HONG KONG) LTD | 0.02% | 0.00% | 18,839 | 18,839 | 100.00% | 71,777 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.02% | 0.00% | 17,761 | 17,761 | 100.00% | 67,669 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.04% | - | 29,074 | 14,769 | 103.24% | 110,608 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.02% | - | 14,618 | 14,618 | 100.00% | 55,695 | Jun 30, 2024 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.69% | 0.00% | 522,375 | 14,226 | 2.80% | 1,990,249 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.05% | 0.00% | 35,283 | 10,248 | 40.93% | 134,428 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.01% | 0.00% | 8,135 | 8,135 | 100.00% | 30,994 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.10% | - | 74,923 | 7,496 | 11.12% | 285,457 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.01% | 0.00% | 7,092 | 7,092 | 100.00% | 27,021 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.01% | 0.00% | 7,064 | 3,717 | 111.05% | 26,914 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 3,126 | 3,126 | 100.00% | 11,910 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.16% | 0.00% | 124,686 | 2,539 | 2.08% | 475,053,000 | Jun 30, 2024 |
| NISA INVESTMENT ADVISORS, LLC | 0.00% | 0.00% | 2,100 | 2,100 | 100.00% | 8,001 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.05% | - | 34,278 | 2,014 | 6.24% | 130,599 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.00% | - | 1,481 | 1,481 | 100.00% | 5,642 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.00% | - | 2,939 | 886 | 43.16% | 11,000 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | 0.00% | 128,033 | 663 | 0.52% | 487,806 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.01% | - | 5,792 | 518 | 9.82% | 22,068 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.03% | 0.00% | 21,565 | 399 | 1.89% | 82,155 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.48% | 0.00% | 361,951 | 319 | 0.09% | 1,379,205 | Jun 30, 2024 |
As of Jun 30 2024, Prelude Therapeutics's largest institutional buyer is Y-INTERCEPT (HONG KONG) LTD. The company purchased 18.84K stocks of PRLD, valued at $71.78K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | - | - | - | -101,850 | -100.00% | - | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.18% | 0.00% | 891,298 | -50,673 | -5.38% | 3,397,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.27% | 0.00% | 206,600 | -38,200 | -15.60% | 787,146 | Jun 30, 2024 |
| CERITY PARTNERS LLC | - | - | - | -32,500 | -100.00% | - | Jun 30, 2024 |
| PALE FIRE CAPITAL SE | - | - | - | -31,481 | -100.00% | - | Jun 30, 2024 |
| BLACKROCK INC. | 1.41% | 0.00% | 1,068,916 | -28,558 | -2.60% | 4,072,569 | Jun 30, 2024 |
| ZACKS INVESTMENT MANAGEMENT | - | - | - | -18,457 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.06% | 0.00% | 43,135 | -17,462 | -28.82% | 164,344 | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.06% | 0.00% | 48,727 | -15,160 | -23.73% | 185,650 | Jun 30, 2024 |
| AMUNDI | - | - | - | -15,130 | -100.00% | - | Jun 30, 2024 |
| MORGAN STANLEY | 0.38% | 0.00% | 287,354 | -8,851 | -2.99% | 1,094,820 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.02% | 0.00% | 12,345 | -7,721 | -38.48% | 47,034 | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -7,333 | -100.00% | - | Jun 30, 2024 |
| VANGUARD GROUP INC | 1.33% | 0.00% | 1,010,565 | -6,434 | -0.63% | 3,850,253 | Jun 30, 2024 |
| BARCLAYS PLC | 0.02% | - | 14,601 | -5,786 | -28.38% | 56,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.01% | - | 10,934 | -4,721 | -30.16% | 41,659 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.05% | - | 36,276 | -3,792 | -9.46% | 138,212 | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.01% | 0.00% | 11,074 | -2,772 | -20.02% | 42,192 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.09% | 0.00% | 70,045 | -2,217 | -3.07% | 266,871 | Jun 30, 2024 |
| FMR LLC | 0.01% | - | 9,575 | -1,975 | -17.10% | 36,481 | Jun 30, 2024 |
As of Jun 30 2024, Prelude Therapeutics's biggest institutional seller is MILLENNIUM MANAGEMENT LLC. The company sold -0.10M shares of PRLD, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| Y-INTERCEPT (HONG KONG) LTD | 0.02% | 0.00% | 18,839 | 18,839 | 100.00% | 71,777 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.02% | - | 14,618 | 14,618 | 100.00% | 55,695 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.01% | 0.00% | 8,135 | 8,135 | 100.00% | 30,994 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.01% | 0.00% | 7,092 | 7,092 | 100.00% | 27,021 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 3,126 | 3,126 | 100.00% | 11,910 | Jun 30, 2024 |
| NISA INVESTMENT ADVISORS, LLC | 0.00% | 0.00% | 2,100 | 2,100 | 100.00% | 8,001 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.00% | - | 1,481 | 1,481 | 100.00% | 5,642 | Jun 30, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 64 | 64 | 100.00% | 244 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | - | - | 19 | 19 | 100.00% | 73 | Jun 30, 2024 |
Prelude Therapeutics's largest new institutional shareholder by number of shares is Y-INTERCEPT (HONG KONG) LTD, purchased 18.84K shares, valued at $71.78K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | - | - | - | -101,850 | -100.00% | - | Jun 30, 2024 |
| CERITY PARTNERS LLC | - | - | - | -32,500 | -100.00% | - | Jun 30, 2024 |
| PALE FIRE CAPITAL SE | - | - | - | -31,481 | -100.00% | - | Jun 30, 2024 |
| ZACKS INVESTMENT MANAGEMENT | - | - | - | -18,457 | -100.00% | - | Jun 30, 2024 |
| AMUNDI | - | - | - | -15,130 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -7,333 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -1 | -100.00% | - | Jun 30, 2024 |
Prelude Therapeutics's largest sold out institutional shareholder by shares sold is MILLENNIUM MANAGEMENT LLC, sold -0.10M shares, valued at -, as of undefined.
Prelude Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 0.20% | 670,681 | -100,412 | -13.02% | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.13% | 1,068,192 | - | - | Jan 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.05% | 114,000 | -25,149 | -18.07% | Mar 28, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND IV | 0.04% | 118,000 | - | - | Mar 31, 2024 |
| IndexIQ ETF Trust | 0.04% | 83,060 | - | - | Jan 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.02% | 39,548 | - | - | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.02% | 336,100 | - | - | Jan 31, 2024 |
| ETFis Series Trust I | 0.02% | 24,180 | - | - | Jan 31, 2024 |
| MFS SERIES TRUST I | 0.02% | 327,699 | - | - | Feb 29, 2024 |
| FIDELITY SECURITIES FUND | 0.01% | 894,468 | - | - | Jan 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.01% | 4,679 | - | - | Mar 31, 2024 |
| FIDELITY DESTINY PORTFOLIOS | 0.00% | 10,151 | - | - | Mar 31, 2024 |
| Fidelity Central Investment Portfolios LLC | 0.00% | 224,800 | - | - | Feb 29, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 26,682 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.00% | 254,056 | - | - | Feb 29, 2024 |
| FIDELITY PURITAN TRUST | 0.00% | 183,900 | - | - | Jan 31, 2024 |
| MFS VARIABLE INSURANCE TRUST | 0.00% | 102,499 | 574 | 0.56% | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 1,577 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 51,871 | 8,312 | 19.08% | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 926,684 | -189,773 | -17.00% | Mar 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.00% | 24,000 | - | - | Jan 31, 2024 |
| Nushares ETF Trust | 0.00% | 14,906 | - | - | Jan 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 54,870 | - | - | Feb 29, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 314,102 | - | - | Feb 29, 2024 |
| UBS FUNDS | 0.00% | 8,149 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.00% | 30,200 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 251 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 2,993 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 40,990 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 176,835 | 17,211 | 10.78% | Feb 29, 2024 |
| Trust for Advised Portfolios | 0.00% | 10,887 | - | - | Dec 31, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 13,754 | - | - | Mar 31, 2024 |
| FIDELITY INVESTMENT TRUST | 0.00% | 75,800 | - | - | Jan 31, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 442,180 | - | - | Feb 29, 2024 |
| Direxion Shares ETF Trust | 0.00% | 51,658 | - | - | Jan 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 4,038 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 819 | - | - | Mar 31, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 19,212 | - | - | Feb 29, 2024 |
| VANGUARD WORLD FUND | 0.00% | 40,217 | - | - | Feb 29, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 86,148 | 3,001 | 3.61% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 3,812 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 11,964 | - | - | Mar 28, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.00% | 800 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 6,107 | - | - | Feb 29, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 429 | -793 | -64.89% | Mar 31, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 6,345 | - | - | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 3,400 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 6,792 | 2,014 | 42.15% | Mar 28, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,020 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 459 | - | - | Mar 31, 2024 |
| MFS SERIES TRUST XV | 0.00% | 701 | -16 | -2.23% | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 525,946 | 15,221 | 2.98% | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 61,738 | 6,053 | 10.87% | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 8,255 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 29,358 | - | - | Mar 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 24,682 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 5,083 | 2,317 | 83.77% | Jan 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 90 | - | - | Dec 31, 2023 |
| FIDELITY COVINGTON TRUST | 0.00% | 393 | - | - | Jan 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,751 | 1,285 | 87.65% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 5,711 | 228 | 4.16% | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,847 | 1,370 | 287.21% | Feb 29, 2024 |
| PACIFIC FUNDS SERIES TRUST | 0.00% | 5,152 | 1,964 | 61.61% | Mar 31, 2023 |
| SPDR SERIES TRUST | 0.00% | 649,460 | - | - | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 1,281 | - | - | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 1,794 | -1,980 | -52.46% | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 44,276 | -3,055 | -6.45% | Mar 31, 2024 |
| ADVANCED SERIES TRUST | 0.00% | 37,478 | - | - | Mar 28, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 45 | - | - | Dec 31, 2023 |
| Guggenheim Active Allocation Fund | 0.00% | 64 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 300 | - | - | Mar 28, 2024 |
| HC CAPITAL TRUST | 0.00% | 333 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 116 | -9 | -7.20% | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 1,200 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 20,318 | 2,097 | 11.51% | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 2,181 | -2,332 | -51.67% | Feb 29, 2024 |
| J.P. Morgan Exchange-Traded Fund Trust | 0.00% | 2,962 | - | - | Jan 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 6,582 | - | - | Jan 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 6 | - | - | Dec 31, 2023 |
| Brighthouse Funds Trust II | 0.00% | 4,148 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 1,686 | 67 | 4.14% | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 13,804 | - | - | Jan 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 9,400 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 11,257 | - | - | Mar 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 1,003 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 707 | - | - | Jan 31, 2024 |
| Bridge Builder Trust | 0.00% | 7,808 | - | - | Mar 31, 2024 |
| FIDELITY HASTINGS STREET TRUST | 0.00% | 11,400 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 17,193 | - | - | Feb 29, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 967 | - | - | Dec 31, 2023 |
| Advisors' Inner Circle Fund III | 0.00% | 86 | - | - | Jan 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 4,712 | - | - | Mar 28, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 2 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 1,647 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 1,980 | - | - | Jan 31, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 49 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 3,000 | - | - | Feb 29, 2024 |
Prelude Therapeutics's largest mutual fund holder by % of total assets is "T. Rowe Price Health Sciences Fund, Inc.", owning 670.68K shares, compromising 0.20% of its total assets.
Prelude Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 16 | -72.41% |
| 31 Mar, 24 | 58 | 1.75% |
| 31 Dec, 23 | 57 | -3.39% |
| 30 Sep, 23 | 59 | 7.27% |
| 30 Jun, 23 | 55 | - |
| 31 Mar, 23 | 55 | -9.84% |
| 31 Dec, 22 | 61 | 19.61% |
| 30 Sep, 22 | 51 | -12.07% |
| 30 Jun, 22 | 58 | -13.43% |
| 31 Mar, 22 | 67 | -9.46% |
| 31 Dec, 21 | 74 | 21.31% |
| 30 Sep, 21 | 61 | 8.93% |
| 30 Jun, 21 | 56 | -8.20% |
| 31 Mar, 21 | 61 | 19.61% |
| 31 Dec, 20 | 51 | 34.21% |
| 30 Sep, 20 | 38 | - |
As of 30 Jun 24, 16 institutions are holding Prelude Therapeutics's shares, representing a decrease of -72.41% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 1,412,581 | -95.87% |
| 31 Mar, 24 | 34,212,156 | -1.48% |
| 31 Dec, 23 | 34,725,237 | -5.16% |
| 30 Sep, 23 | 36,614,222 | -5.02% |
| 30 Jun, 23 | 38,547,583 | 22.33% |
| 31 Mar, 23 | 31,510,361 | 1.11% |
| 31 Dec, 22 | 31,163,427 | -2.02% |
| 30 Sep, 22 | 31,806,047 | -2.80% |
| 30 Jun, 22 | 32,720,611 | -4.02% |
| 31 Mar, 22 | 34,089,584 | -2.90% |
| 31 Dec, 21 | 35,107,238 | -2.35% |
| 30 Sep, 21 | 35,953,918 | 4.37% |
| 30 Jun, 21 | 34,447,652 | 5.84% |
| 31 Mar, 21 | 32,545,678 | -6.08% |
| 31 Dec, 20 | 34,651,491 | 3.99% |
| 30 Sep, 20 | 33,322,061 | - |
Prelude Therapeutics (PRLD) has 1.41M shares outstanding as of 30 Jun 24, down -95.87% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 1.87% | 0.06% |
| 31 Mar, 24 | 56.68% | 1713434.09% |
| 31 Dec, 23 | 0.06% | 0.00% |
| 30 Sep, 23 | 65.10% | 1.00% |
| 30 Jun, 23 | 80.75% | 1.85% |
| 31 Mar, 23 | 66.01% | 1.53% |
| 31 Dec, 22 | 65.79% | 1.46% |
| 30 Sep, 22 | 67.03% | 1.40% |
| 30 Jun, 22 | 69.21% | 1.32% |
| 31 Mar, 22 | 72.43% | 1.26% |
| 31 Dec, 21 | 75.78% | 1.26% |
| 30 Sep, 21 | 77.60% | 1.39% |
| 30 Jun, 21 | 74.79% | 1.44% |
| 31 Mar, 21 | 72.13% | 1.22% |
| 31 Dec, 20 | 76.80% | 1.41% |
| 30 Sep, 20 | 73.85% | - |
As of 30 Jun 24, Prelude Therapeutics is held by 1.87% institutional shareholders, representing a 0.06% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 8 | -63.64% |
| 31 Mar, 24 | 22 | -35.29% |
| 31 Dec, 23 | 34 | 13.33% |
| 30 Sep, 23 | 30 | -25.00% |
| 30 Jun, 23 | 40 | 60.00% |
| 31 Mar, 23 | 25 | - |
| 31 Dec, 22 | 25 | 25.00% |
| 30 Sep, 22 | 20 | -25.93% |
| 30 Jun, 22 | 27 | -15.63% |
| 31 Mar, 22 | 32 | -38.46% |
| 31 Dec, 21 | 52 | 57.58% |
| 30 Sep, 21 | 33 | 3.13% |
| 30 Jun, 21 | 32 | -33.33% |
| 31 Mar, 21 | 48 | 29.73% |
| 31 Dec, 20 | 37 | -2.63% |
| 30 Sep, 20 | 38 | - |
8 institutional shareholders have increased their position in PRLD stock as of 30 Jun 24 compared to 22 in the previous quarter (a -63.64% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 4 | -81.82% |
| 31 Mar, 24 | 22 | 57.14% |
| 31 Dec, 23 | 14 | -12.50% |
| 30 Sep, 23 | 16 | 100.00% |
| 30 Jun, 23 | 8 | -46.67% |
| 31 Mar, 23 | 15 | -37.50% |
| 31 Dec, 22 | 24 | 33.33% |
| 30 Sep, 22 | 18 | -10.00% |
| 30 Jun, 22 | 20 | -13.04% |
| 31 Mar, 22 | 23 | 64.29% |
| 31 Dec, 21 | 14 | 7.69% |
| 30 Sep, 21 | 13 | 8.33% |
| 30 Jun, 21 | 12 | 50.00% |
| 31 Mar, 21 | 8 | 14.29% |
| 31 Dec, 20 | 7 | - |
| 30 Sep, 20 | - | - |
4 institutional shareholders have reduced their position in PRLD stock as of 30 Jun 24 compared to 22 in the previous quarter (a -81.82% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 16 | -72.41% | 1,412,581 | -95.87% | 1.87% | 0.06% | 8 | -63.64% | 4 | -81.82% |
| 31 Mar, 24 | 58 | 1.75% | 34,212,156 | -1.48% | 56.68% | 1713434.09% | 22 | -35.29% | 22 | 57.14% |
| 31 Dec, 23 | 57 | -3.39% | 34,725,237 | -5.16% | 0.06% | 0.00% | 34 | 13.33% | 14 | -12.50% |
| 30 Sep, 23 | 59 | 7.27% | 36,614,222 | -5.02% | 65.10% | 1.00% | 30 | -25.00% | 16 | 100.00% |
| 30 Jun, 23 | 55 | - | 38,547,583 | 22.33% | 80.75% | 1.85% | 40 | 60.00% | 8 | -46.67% |
| 31 Mar, 23 | 55 | -9.84% | 31,510,361 | 1.11% | 66.01% | 1.53% | 25 | - | 15 | -37.50% |
| 31 Dec, 22 | 61 | 19.61% | 31,163,427 | -2.02% | 65.79% | 1.46% | 25 | 25.00% | 24 | 33.33% |
| 30 Sep, 22 | 51 | -12.07% | 31,806,047 | -2.80% | 67.03% | 1.40% | 20 | -25.93% | 18 | -10.00% |
| 30 Jun, 22 | 58 | -13.43% | 32,720,611 | -4.02% | 69.21% | 1.32% | 27 | -15.63% | 20 | -13.04% |
| 31 Mar, 22 | 67 | -9.46% | 34,089,584 | -2.90% | 72.43% | 1.26% | 32 | -38.46% | 23 | 64.29% |
| 31 Dec, 21 | 74 | 21.31% | 35,107,238 | -2.35% | 75.78% | 1.26% | 52 | 57.58% | 14 | 7.69% |
| 30 Sep, 21 | 61 | 8.93% | 35,953,918 | 4.37% | 77.60% | 1.39% | 33 | 3.13% | 13 | 8.33% |
| 30 Jun, 21 | 56 | -8.20% | 34,447,652 | 5.84% | 74.79% | 1.44% | 32 | -33.33% | 12 | 50.00% |
| 31 Mar, 21 | 61 | 19.61% | 32,545,678 | -6.08% | 72.13% | 1.22% | 48 | 29.73% | 8 | 14.29% |
| 31 Dec, 20 | 51 | 34.21% | 34,651,491 | 3.99% | 76.80% | 1.41% | 37 | -2.63% | 7 | - |
| 30 Sep, 20 | 38 | - | 33,322,061 | - | 73.85% | - | 38 | - | - | - |
Prelude Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Prelude Therapeutics's stock was made by Huang Jane on Jul 08 2024, selling 9,375 shares at - per share (valued at -).
Prelude Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 2 | 2 | 100.00% |
| Q1 2024 | 7 | 2 | 350.00% |
| Q4 2023 | 4 | - | - |
| Q3 2023 | 1 | 2 | 50.00% |
| Q2 2023 | 18 | 2 | 900.00% |
| Q1 2023 | 6 | - | - |
| Q4 2022 | 3 | - | - |
| Q2 2022 | 11 | 1 | 1100.00% |
| Q1 2022 | 8 | 1 | 800.00% |
| Q4 2021 | 10 | 12 | 83.33% |
| Q3 2021 | 18 | 33 | 54.55% |
| Q2 2021 | 21 | 53 | 39.62% |
| Q1 2021 | 6 | 1 | 600.00% |
| Q3 2020 | 39 | 38 | 102.63% |
| Q1 2020 | 5 | - | - |
2 total buy trades, and 2 total sell trades (buy/sell ratio of 1.00%) were made by Prelude Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | 7 | 1 | 700.00% |
| Q1 2023 | - | - | - |
| Q4 2022 | 2 | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | 2 | 6 | 33.33% |
| Q3 2021 | - | 23 | - |
| Q2 2021 | - | 37 | - |
| Q1 2021 | 4 | - | - |
| Q3 2020 | 14 | - | - |
| Q1 2020 | 5 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Prelude Therapeutics's stocks.
Prelude Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| NRIX | Nurix Therapeutics, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| BCEL | Atreca, Inc. |
| PASG | Passage Bio, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| PEPG | PepGen Inc. |
| MOLN | Molecular Partners AG |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
PRLD Ownership FAQ
Who Owns Prelude Therapeutics?
Prelude Therapeutics is owned by institutional shareholders (1.87%), insiders (9.06%), and public (89.07%). The largest institutional shareholder of Prelude Therapeutics is ORBIMED ADVISORS LLC (14.40% of total shares) and the top mutual fund owner is T. Rowe Price Health Sciences Fund, Inc. (0.20% of total shares).
Who are the major institutional shareholders of Prelude Therapeutics?
Prelude Therapeutics's major institutional shareholders are ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BOXER CAPITAL, LLC, and BLACKROCK INC.. The top five shareholders own together 38.03% of the company's share outstanding.
How many Prelude Therapeutics shareholders are there?
As of Jun 2024, there are 16 institutional shareholders of Prelude Therapeutics.
What percentage of Prelude Therapeutics is owned by ORBIMED ADVISORS LLC?
ORBIMED ADVISORS LLC owns 10.91M shares of Prelude Therapeutics, representing 14.40% of the company's total shares outstanding, valued at $41.56M (as of Jun 2024).
What percentage of Prelude Therapeutics is owned by BAKER BROS. ADVISORS LP?
As of Jun 2024, BAKER BROS. ADVISORS LP holds 10.12M shares of Prelude Therapeutics (PRLD), compromising 13.37% of the company, valued at $38.57M.
What percentage of Prelude Therapeutics is owned by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)?
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is the third largest holder of Prelude Therapeutics. The company owns 4.13M of the company's shares outstanding (worth $15.75M).